The European Summit for Clinical Nanomedicne and Targeted Medicine

The Translation to Knowledge Based Nanomedicne

8th Conference And Exhibition, June 28 - July 1, 2015

Sunday, June 28, 2015 • General Assembly of the European Society for Nanomedicine (15.30 h) • Meeting of the International Society for Nanomedicine (16.30 h) • Editorial Board Meeting, European Journal of Nanomedicine (18.00 h) • Welcome Dinner for Speakers & invited Guests [19.45 Swissôtel Le Plaza, 1st Floor]

Co-founded by the Swiss Confederation. Swiss Derpartment of Economic Affairs, Education and Research


Call for Papers and Posters

Scientific Committee: • Prof. Dr. med. Patrick Hunziker, University Hospital Basel (CH) (Chairman) • Prof. Dr. Yechezkel Barenholz, Hebrew University, Hadassah Medical School, Jerusalem (IL) • Beat Löffler, MA, European Foundation for Clinical Nanomedicine (CLINAM), Basel (CH) • Prof. Dr. Gert Storm, Institute for Pharmaceutical Sciences, Utrecht University, (NL) • Prof. Dr. Marisa Papaluca Amati, European Medicines Agency, London (GB) • Prof. Dr. med. Janos Szebeni, Bay Zoltan Ltd and Semmelweis/Miskolc Universities, Budapest (HU) • Prof. Dr. med. Christoph Alexiou, Head and Neck Surgery, University Hospital Erlangen (D) • Prof. Dr. Claus‐Michael Lehr, Helmholtz‐Institute for Pharmaceutical Research Saarland (HIPS), Saarbrucken (D) • Prof. Dr. Gerd Binnig, Founder of Definiens AG, Nobel Laureate, Munich (DE) Patrick Boisseau, CEA‐Léti, Chairman of the ETPN, Grenoble (FR) • Prof. Dr. Viola Vogel, Laboratory for Biologically Oriented Materials, ETH, Zürich (CH) • Prof. Dr. Jan Mollenhauer, Director Lundbeckfonden Center of Excellence University of Southern Denmark, Odense (DK) Dr. Yanay Ofran, Systems Biology & Functional Genomics, Bar Ilan University, Ramat Gan (IL)

Venue: Congress Center, Messeplatz 21, 4058 Basel, Switzerland, Phone + 41 58 206 28 28 This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Organizers Office: CLINAM‐Foundation, Alemannengasse 12, 4016 Basel Phone +41 61 695 93 95 This e-mail address is being protected from spambots. You need JavaScript enabled to view it

1. Introduction

Worldwide Platform

The CLINAM‐Foundation and all Collaborators of the Summit have the pleasure to announce the European Summit for Clinical Nanomedicine and Targeted Medicine in Basel. The Meeting has become a worldwide interdisciplinary Nanomedicine platform with more than 500 participants from 42 countries joining the last Summit in 2014. Its major goal is the support of development and application of Nanomedicine and Targeted Medicine to the benefit of the patient and mankind. The CLINAM Summit has achieved a unique position in bringing together all stakeholders relevant to the field of Nanomedicine and Targeted Medicine, including the regulatory authorities from all continents, clinicians, researchers and industrial innovators from this area.

Catalyst Function

The CLINAM Summit has emerged as valuable market place to launch collaboration and novel projects, including numerous EUwide efforts, in Nanomedicine and Targeted Medicine. The field represents one of the most exciting and promising arenas for novel technologies, assisting to combat devastating diseases in developing and industrialized countries and to generate novel concepts for addressing the challenges associated with demographic changes in the European society. Nanomedicine and Targeted Medicine are the catalyst disciplines for developing diagnostics and treatments accounting for the nanoscale, molecular and cellular origin of disease and one of the enabling disciplines for Knowledge Based Medicine of tomorrow.

Translation from Innovation to Product

The pathway from the innovative idea to the application, the development, regulatory approval and commercialization of a nanomedical drug is complex and first and foremost requires understanding the cause of the disease. The translation process from research findings to applications in Nanomedicine and Targeted Medicine has been well developing and is now on the agenda of the global players in the pharmaceutical industry. The decision makers in pharmaceutical companies start appreciating the quality and potential of Nanomedicine and Targeted Medicine for significantly increasing the output of diagnostics and therapeutic products, less invasive and with reduced side effects. By bringing the relevant stakeholders together, the CLINAM Summit has achieved an actively promoting role in this process.

Towards Personalized Medicine

In the next decades medicine will experience a transformation to personalized diagnosis and treatment, taking the individual aspects of the patient and his/her disease into consideration. Key roles play high‐resolution molecular profiling techniques, which have been enabled and made inexpensive by Nanomedicine. The CLINAM Summit offers excellent opportunities for the huge number of organizations, which are worldwide working towards this goal, to exchange know‐how and to launch joint‐ventures for further acceleration of the process.

The 3 Medical Focus‐Fields for 2015

As all years the scientific committee votes for 3 fields in medicine to be extra focused on. For this Summit the topics chosen are: ● Infection and Inflammation ● Cancer and ● Diabetes.

Why to Participate as a Speaker in the CLINAM Summit

At CLINAM 8/2015 you will have the unique opportunity to present and discuss your work with experts from all different fields that comprise Nanomedicine and Targeted Medicine, including regulatory authorities, industrial, academic, and clinical experts. This is the most comprehensive feedback that can be obtained. CLINAM is the Reference Meeting

Collaborating Organizations

The Board of the CLINAM Foundation is grateful for the collaboration with many organizations that are willing to bring into this meeting highly skilled expertise and make the Summit to an International Melting Pot for the Medicine of the Future on the Neutral Platform of the non‐for profit Foundation for Clinical Nanomedicine (CLINAM) in Basel.

Call for Papers and Posters:

Knowledge Fields

CLINAM invites on interdisciplinary level members in the field of Clinic, Engineering, Industry, Venture, all related Science Faculties, young members from universities and academies and highly skilled youngsters, political decision makers that work in the field and members of regulatory authorities. Debates are dedicated to the following topics: ● Targeted therapies ● Late breaking and ongoing clinical trials ● novel materials, technologies and devices ● Novel drug delivery and diagnostics for diseases such as ● cancer, ● diabetes, ● infection and ● inflammation, ● brain diseases, ● cardiovascular disease, ● Rare disease incl. ● Malaria, ● Chikungunya, ● Dengue, ● Ebola …and further diseases ● Translation of novel technologies to market and patient ● Regulatory pathways and harmonization of vision and of standards ● Immunology, toxicology and implications ● Financing developments / Investors for Nanomedicine‐projects and startups ● Nanomedicine market trends ● Ethical and societal implications ● Results of European Union research projects and national initiatives ● Future European and national healthcare policies ● Patients Care and interests of Patient groups, ethical concerns ● Non Biological Complex Drugs (NBCD) ● Life science tools for translational research and molecular diagnostics ● Models Animals Humans (Replace Refine Reduce) ● The Systems Biology of Nanomedicine ● Nanophysics as Handle to Novel Diagnostic Vehicles/What to Measure why? ● Personalized Nanomedicine ● Nanostructures & Composites ● Knowledge Based Medicine ● Development Feedback from Nano‐Clinical Centers in the world ● Antibodies vs. Nanoparticle delivery ● Nanomedical Imaging ● Translation Process of Drugs and devices ● Regenerative Nanomedicne ● Cellular Handlich and novel Celluralr Targets ... and further related topics.

3. Submissions of Papers and Posters

General Scope

Papers must cover original research aimed at future or current applications of nanoscience and targeted medicine including clinical trial designs, reports of ongoing and completed clinical trials, preclinical work, and technology papers with clinical longterm vision. All fields leading to the development of personalized medicine are also issues of interest.


Clinical Topics:
Nanomedicine and targeted medicine for cardiovascular disease, rheumatic disease, oncology, gastrointestinal/hepatic disease, bacterial infection, viral infection, parasitic infection, implantology, inflammation, hematology, diabetes, neurology, neurosurgery, orphan diseases, eye and ear disease, tuberculosis, HIV, Ebola, tissue repair, orthopedics, …etc.

Technology Topics:
Nanosystems, nanoparticles, nanoanalytics and diagnostics, toxicology, nano‐imaging, targeted drug delivery using nanoparticles, GMP and quality assurance, propositions for solving a medical problem in a novel way by the use of nanotechnology, novel concepts and ideas if they can be supported by thorough reasoning and could lead to novel research and solutions, materials for use in nanotechnology and targeted medicine, concepts, diagnosis and therapy in the field of personalized medicine: clinical diagnosis and management on the individual patient's clinical signs and symptoms, medical and family history, and data from laboratory and imaging evaluation to diagnose and treat illnesses, genetic testing leading to more personalized treatments. Also relevant novel tools for translational research and diagnostics are of high interest, …etc.

Implications Topics:
Implications of Nanomedicine for society, developing countries, environment, risks and benefits, public health finance, health economics, and other subjects, etc.

Strategy, Government and Politics Topics:
Strategy building and policy processes in Nanomedicine. Strategic approaches towards establishing a unified funding area for nanotechnologies for medical research. Policy processes to foster leadership in Nanomedicine, regulatory authority topics as well as financial and marketing matters …etc.

Industry Topics:
Industry projects and solutions in Nanomedicine and targeted medicine, tools related to Nanomedicine and targeted medicine. Industry models for the Future large scale production, Good Manufacturing Practice, etc.

Exhibitors Topics:
Some integrated interventions of exhibitors at CLINAM 8/ 2015 that are of scientific or technical high relevance and do not have the only purpose of promoting the trade mark.

4. Sending Paper Abstract / Poster Abstract, Format, Procedure, Registration

Mailing Address
All correspondence regarding Submission of Posters or Papers has to be sent to: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Paper or Poster Abstract
Send us your paper abstract or poster abstract, (Microsoft Word, RTF, or Open document file format, using Times New Roman, font size 11, single spacing). The submission must not be longer than three pages, including metadata and figures (one figure is obligatory). All illustrations, figures, and tables must be placed within the text at the appropriate points.)For control purposes you may send in addition a pdf). Index your file as follows: Last name.First name_Submission15.xx (xx = docx, or rtf, doc or word 13 document).

Add a short CV (1 page maximum,same format) and your portrait photo (in gif or jpg 600 dpi and not word copy paste!) Index your file as follows: Last name.First name_CV15.xx and Last name.First of the abstractName_Picture15.xx . Special Registration Fee

Decision for Acceptance or Declination of Oral Presentations until deadline April 10, 2015
The decision to acceptance or rejection of your submitted work will be taken by APRIL 10, 2015. You will then receive within 10 Days a Decision Form, which – in the case of acceptance ‐ has to be returned within 3 days of receipt. After this you have to register according to your category within one week. If you summited a paper for oral presentation and it was not accepted you are eligible for a Poster. In this case you get a letter from the organizer and may decide to present your topic in a poster. Poster only Submissions Deadline until May 2, 2015. You will receive within one week a Decision Form, which has to be returned within 3 days of receipt. After this you have to register according to your category within one week.

Posters‐only shall also be accepted for a longer period until 12 Days before the Summit. These Posters shall not be included in the proceedings of the conference and you have to hand out descriptions by yourself.

Reduced Registration Fee for accepted Poster or Paper Submitters
Those receiving an acceptance for an oral speech or for a poster profit of a special registration Fee of 460. ‐‐ €, submitting students at 340. ‐ ‐ €

5. University Village 2015

The University Village is the space for universities and research institutes, giving them opportunity to present novel approaches, new research projects and initial outcomes of research and experimental results as well as first patents. Researchers and engineers can use the foyer to show the existing tools, instruments and materials in the field of regenerative medicine, diagnostics, targeted drug delivery systems, novel materials for nanoparticles, imaging, biomaterials / biosensors / biomarkers, Nanomedicine‐related medical tools and medical instrumentation as well as existing nanobased clinical medications.

6. “Small Speech” Sessions

Poster presenters and University Village members are eligible for presentations in a special session of Small Speeches, 3 minutes in length and serving to highlight the research activities in Nanotechnology and Targeted Medicine. They must comprise three slides, • Slide 1: general introduction to the topic • Slide 2: some of the highlights of submitters’ work and institutions’ work • Slide 3: the proof as to how the work fits into the area of Nanomedicine including a glimpse into the future. Application for Small Talk Sessions is possible any time after acceptance of your poster in writing.

7. Some Speakers at the 2015 Summit

• Prof. Dr. med. Christoph Alexiou, Head and Neck Surgery, University Hospital Erlangen (DE) • Prof. Dr. Yechezkel Barenholz, Hebrew University, Hadassah Medical School, Jerusalem (IL) • Prof. Dr. Lajos P. Balogh, Editor‐in‐Chief, Nanomedicine: Nanotechnology,

Biology and Medicine (Elsevier), Boston (USA) • Prof. Dr. Gerrit Borchard, Professor Biopharmaceutical Sciences, President of the Swiss Society of Pharmaceutical Sciences, Vice President of the European Federation of Pharmaceutical Sciences, School of Pharmaceutical Sciences, Universities of Geneva and Lausanne (CH) • Dr. Donald Bruce, Edinethics Ltd., Edinburgh, Scotland (UK)

Prof. Dr. Kenneth A. Dawson, Professor of Physical Chemistry School of Chemistry & Chemical Biology; Director of the Centre for BioNano Interactions, Dublin (IRL) • Prof. Dr. Rutledge EllisBehnke, Director of the Nanomedicine Translational Think Tank, Department of Ophthalmology, Medical Faculty Mannheim, University of Heidelberg (DE) Andreas Falk, MSc., CEO, BioNanoNet Research Association, Graz(AT) • Prof. Dr. Alke Fink, Adolphe Merkle Institute, University of Fribourg, Marly (CH) • Prof. Dr. M. Foldvari, DPharmSci, Canada Research Chair in Bionanotechnology and Nanomedicine, School of Pharmacy, University of Waterloo (CA) • Prof. Dr. Ursula GrafHausner, Zürcher Hochschule für Angewandte Wissenschaften, Institut für Chemie und Biologische Chemie ICBC , Campus Reidbach, Wädenswil (CH) • Prof Dr.Ing. Heinrich Hofmann, Director Powder Technology Laboratory, Institute of Materials EPFL, Lausanne (CH) • Prof. Dr. med. Patrick Hunziker, President of the European Society for Nanomedicine, Basel, (CH) • Dr. Silke Krol, Fondazione IRCCS Istituto Neurologico "Carlo Besta" IFOM‐IEO‐campus, Milan (I) • Dr. Twan Lammers, PhD, DSc, Experimental Molecular Imaging, RWTH Aachen, Aachen (D) and Department of Targeted Therapeutics, University of Twente, Enschede (NL) • Prof. Dr. med. Dong Soo Lee, PhD, Dept. of Nuclear Medicine, College of Medicine, National University Seoul, Seoul (ROK) • Dr. Julianna Lisziewicz, President and Chief Scientific Officer eMMUNITY, Inc., Budapest (HU) • Beat Löffler, MA, CEO of the European Foundation for Nanomedicine, Basel (CH) • Prof. Dr. med. Harald Mangge, Head of the Research Unit on Lifestyle and Inflammation‐associated Risk Biomarkers, Vice‐Speaker of the Cardiovascular RF Clinical Institute for Medical and Chemical Laboratory Diagnosis, Medical University of Graz (A) • Dr. Mira MarcusKalish, Senior Research Fellow, International Research Affairs, Tel Aviv University, Tel Aviv (IL) • Dr. Dr. Konstantinos Mitsakakis, MSc., Laboratory for MEMS Applications, Department of Microsystems Engineering (IMTEK), University of Freiburg, Freiburg i.Br. (D) • Prof. Dr. Jan Mollenhauer, University of Southern Denmark, Head Molecular Oncology, Odense (DK)• Prof. Dr. Bert Müller, Thomas Straumann‐Chair for Materials Science in Medicine, University Basel (CH)• Prof. Dr. Marisa Papaluca Amati, Head of Scientific Support and Projects, European Medicines Agency, London (GB) • Dr. Bernd Riebesehl, Principal Fellow, Novartis Pharma, Basel (CH) • Prof. Dr. Eder Lilia Romero, Programa de Nanomedicinas, Universida Nacional de Quilmes, Buenos Aires (AR) • Prof. Dr. Kirsten Sandvig, PhD, Centre for Cancer Biomedicine, Oslo University Hospital & University of Oslo (N) • Prof. Dr. G. Scoles, University Hospital, University of Udine, (IT) and Biology Department, Temple University, Philadelphia, PA (US) • Dr. Tore Skotland, PhD, Senior Researcher, Centre for Cancer Biomedicine, Oslo University Hospital, Oslo (N) • Dr. Ruth Schmid, Chief Business Developer SINTEF Materials and Chemistry Synthesis and Properties Polymer Particles and Surface Chemistry, Trondheim (N) • Prof. Dr. med. Simo Schwartz, Jr., PhD, Research Center for Nanomedicine (CIBBIM‐Nanomedicine) Vall d'Hebron Univ. Hospital Research Institute, Barcelona (ES) • Prof. Dr. Alejandro Sosnik, Associate Professor, Department of Materials Science and Engineering of the Technion, Israel Institute of Technology, Haifa (IL) • Prof. Dr. Gert Storm, Institute for Pharmaceutical Sciences, Utrecht University, Utrecht (NL) • Dr. Rudolf Strohmeier, Deputy Director General of the DG for Research, Brussels (BE) • Prof. Dr. med. Janos Szebeni, Director, Nanomedicine Research and Education Center, Bay Zoltan Ltd/Semmelweis / Miskolc Universities, Budapest (HU) • Dr. med. Panagiotis N. Trohopoulos, Cardiologist, Founder & Coordinator of the EU FP7 NMP Funded CosmoPHOS‐nano Project, Executive Board Member of the ETPN, Thessaloniki, Greece (GR) • Prof. Dr. Donald Tomalia, Columbia University, NY, Affiliate Professor Virginia Common‐wealth University, Richmond, VA, CEO/Founder NanoSynthons LLC National Dendrimer & Nanotechnology Center, Mt. Pleasant MI, External Faculty (School of Pharmacy), University • Prof. Dr. Viola Vogel, Department of Materials Laboratory for Biologically Oriented Materials, ETH Zürich, Zürich (CH) • Dr. med. Frank F. Weichold, Ph.D., Director of Critical Path and Regulatory Science Initiatives, Office of Regulatory Science & Innovation (ORSI) and Office of the Chief Scientist / Office of the Commissioner Food and Drug Administration (FDA), Silver Spring, MD (USA)• Joy Wolfram, MS, Department of Nanomedicine, The Methodist Hospital Research Institute, Houston, TX (USA); CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, National Center for Nanoscience & Technology of China, Beijing (RC) Prof. Dr. Yuliang Zhao, Deputy
Director‐General, National Center for Nanosciences and Technology of China and Director, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety. Institute of High Energy Physics Chinese Academy of Sciences

8. Target Audience

The faculty includes the pioneers and opinion leaders in the fields of medicine, nanoscience and targeted medicine, who share their experience in an interdisciplinary and interactive manner that widens mutual understanding for both sides The conference and the exhibition are aimed at physicians, as well as nonscientists with a background in pharmacology, biology, physics, chemistry, biophysics, medicine materials science and engineering. The meeting is a particularly useful source of knowledge for the targeted medicine and delivery community. The Conference is also of interest for policymakers, experts from industry in the field of life sciences, developers of new tools and materials for Nanomedicine, and all those investigating the future potential of emerging technologies. Experts from venture companies can acquire knowledge on existing and upcoming developments and novel products in the emerging field of Nanomedicine. And Knowledge Based Medicine. Government authorities can profit from of the regulator’s international sessions.

9. Registration Fees 2015

Registration for the CLINAM‐Summit is only possible online.

10.Organizers Office

European Foundation for Clinical Nanomedicine (CLINAM)
Alemannengasse 12, 4016 Basel, Switzerland
Phone +41 61 695 93 95 Fax +41 61 695 93 90 Mail This e-mail address is being protected from spambots. You need JavaScript enabled to view it